PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Increased circulating M2-like monocytes in patients with breast cancer.

Abstract M2-like tumor-associated macrophages promote breast tumor growth and survival and may migrate into the peripheral blood. However, the frequency of circulating M2-like monocytes in the peripheral blood of breast cancer patients has not been clarified. The objective of this study was to determine the percentages of circulating M2-like monocytes in patients with breast cancer. Immunofluorescence staining for CD68 and CD163 was performed to detect M2-like macrophages in pathological tissues. Flow cytometry was used to assess the frequencies of circulating CD14(+)CD163(+)/CD14(+)CD204(+)/CD14(+)CD163(+)CD204(+) M2-like monocytes in 99 breast cancer patients, 56 patients with benign breast disease, and 60 healthy controls. Receiver operating characteristic curve analysis was used to compare the diagnostic values of circulating M2-like monocytes, carcinoembryonic antigen, and cancer antigen 15-3. The associations among circulating M2-like monocytes and clinical breast cancer parameters were analyzed. The number of CD68(+)CD163(+) M2-like macrophages was significantly higher in breast cancer tissues than in benign tissues. In the peripheral blood, CD14(+)CD163(+)/CD14(+)CD204(+)/CD14(+)CD163(+)CD204(+) M2-like monocytes were elevated in breast cancer patients compared with normal controls and patients with benign breast disease. The area under the receiver operating curve for circulating CD14(+)CD163(+)CD204(+) M2-like monocytes was 0.888 (95% confidence interval: 0.839-0.936), a value higher than those for carcinoembryonic antigen and cancer antigen 15-3. High frequencies of circulating CD14(+)CD204(+) and CD14(+)CD163(+)CD204(+) M2-like monocytes were associated with tumor-node-metastasis stage, lymph node metastasis, histological differentiation, and estrogen receptor expression. Circulating M2-like monocytes may serve as a diagnostic biomarker in breast cancer and have a potential role in reflecting breast cancer progression.
PMID
Related Publications

CD163+CD14+ macrophages, a potential immune biomarker for malignant pleural effusion.

Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma.

A Higher Frequency of CD14+ CD169+ Monocytes/Macrophages in Patients with Colorectal Cancer.

Circulating CD14+CD204+ cells predict postoperative recurrence in non-small-cell lung cancer patients.

Characterization of monocyte/macrophage subsets in the skin and peripheral blood derived from patients with systemic sclerosis.

Authors

Mayor MeshTerms
Keywords

Breast cancer

CD163

CD204

biomarker

diagnosis

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28639912
OWN - NLM
STAT- MEDLINE
DA  - 20170622
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Increased circulating M2-like monocytes in patients with breast cancer.
PG  - 1010428317711571
LID - 10.1177/1010428317711571 [doi]
AB  - M2-like tumor-associated macrophages promote breast tumor growth and survival and
      may migrate into the peripheral blood. However, the frequency of circulating
      M2-like monocytes in the peripheral blood of breast cancer patients has not been 
      clarified. The objective of this study was to determine the percentages of
      circulating M2-like monocytes in patients with breast cancer. Immunofluorescence 
      staining for CD68 and CD163 was performed to detect M2-like macrophages in
      pathological tissues. Flow cytometry was used to assess the frequencies of
      circulating CD14+CD163+/CD14+CD204+/CD14+CD163+CD204+ M2-like monocytes in 99
      breast cancer patients, 56 patients with benign breast disease, and 60 healthy
      controls. Receiver operating characteristic curve analysis was used to compare
      the diagnostic values of circulating M2-like monocytes, carcinoembryonic antigen,
      and cancer antigen 15-3. The associations among circulating M2-like monocytes and
      clinical breast cancer parameters were analyzed. The number of CD68+CD163+
      M2-like macrophages was significantly higher in breast cancer tissues than in
      benign tissues. In the peripheral blood,
      CD14+CD163+/CD14+CD204+/CD14+CD163+CD204+ M2-like monocytes were elevated in
      breast cancer patients compared with normal controls and patients with benign
      breast disease. The area under the receiver operating curve for circulating
      CD14+CD163+CD204+ M2-like monocytes was 0.888 (95% confidence interval:
      0.839-0.936), a value higher than those for carcinoembryonic antigen and cancer
      antigen 15-3. High frequencies of circulating CD14+CD204+ and CD14+CD163+CD204+
      M2-like monocytes were associated with tumor-node-metastasis stage, lymph node
      metastasis, histological differentiation, and estrogen receptor expression.
      Circulating M2-like monocytes may serve as a diagnostic biomarker in breast
      cancer and have a potential role in reflecting breast cancer progression.
FAU - Zhang, Boke
AU  - Zhang B
AD  - 1 Department of Molecular Biology, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai, P.R. China.
FAU - Cao, Manlin
AU  - Cao M
AD  - 2 Department of Rehabilitation Medicine, Shanghai Jiao Tong University Affiliated
      Sixth People's Hospital, Shanghai, P.R. China.
FAU - He, Yiqing
AU  - He Y
AD  - 1 Department of Molecular Biology, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai, P.R. China.
FAU - Liu, Yiwen
AU  - Liu Y
AD  - 1 Department of Molecular Biology, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai, P.R. China.
FAU - Zhang, Guoliang
AU  - Zhang G
AD  - 1 Department of Molecular Biology, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai, P.R. China.
FAU - Yang, Cuixia
AU  - Yang C
AD  - 1 Department of Molecular Biology, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai, P.R. China.
FAU - Du, Yan
AU  - Du Y
AD  - 1 Department of Molecular Biology, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai, P.R. China.
FAU - Xu, Jing
AU  - Xu J
AD  - 3 Department of Clinical Laboratory, Shanghai Jiao Tong University Affiliated
      Sixth People's Hospital, Shanghai, P.R. China.
FAU - Hu, Jiajie
AU  - Hu J
AD  - 1 Department of Molecular Biology, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai, P.R. China.
FAU - Gao, Feng
AU  - Gao F
AD  - 1 Department of Molecular Biology, Shanghai Jiao Tong University Affiliated Sixth
      People's Hospital, Shanghai, P.R. China.
AD  - 3 Department of Clinical Laboratory, Shanghai Jiao Tong University Affiliated
      Sixth People's Hospital, Shanghai, P.R. China.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - 0 (Antigens, CD14)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (M160 protein, human)
RN  - 0 (MSR1 protein, human)
RN  - 0 (Membrane Glycoproteins)
RN  - 0 (Receptors, Cell Surface)
RN  - 0 (Receptors, Scavenger)
RN  - 0 (Scavenger Receptors, Class A)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antigens, CD14/*blood
MH  - Biomarkers, Tumor/*blood
MH  - Breast Neoplasms/*blood/pathology
MH  - Disease Progression
MH  - Female
MH  - Flow Cytometry
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Macrophages/*metabolism/pathology
MH  - Membrane Glycoproteins/*blood
MH  - Middle Aged
MH  - Monocytes/metabolism/pathology
MH  - Receptors, Cell Surface
MH  - Receptors, Scavenger/*blood
MH  - Scavenger Receptors, Class A/*blood
OTO - NOTNLM
OT  - Breast cancer
OT  - CD163
OT  - CD204
OT  - biomarker
OT  - diagnosis
EDAT- 2017/06/24 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/23 06:00
AID - 10.1177/1010428317711571 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317711571. doi: 10.1177/1010428317711571.